The market for GLP-1 drugs, which mimic the naturally occurring hormone GLP-1 to regulate appetite and glucose, has exploded in recent years. Novo Nordisk once dominated it with Ozempic and Wegovy. The sector is now shifting toward Eli Lilly, and the next contest is over who can deliver the therapy as a pill.
Where the two companies stand
Analysts project the global obesity drug market could hit $150 billion by 2030, rivaling the cholesterol and diabetes markets combined. A projection based on data from Axios and Morgan Stanley shows the global GLP-1 market rising steadily from 2023 through 2030.
Lilly’s drugs, Mounjaro and Zepbound, target multiple hormonal pathways for stronger effects. Its new oral GLP-1 pill, orforglipron, showed an average 9.2% weight reduction in adults with type 2 diabetes. That is nearly double the 5.3% seen with Novo Nordisk’s oral semaglutide in comparable early-stage trials. The results put Lilly as a front-runner in the race to deliver effective, non-injectable obesity and diabetes therapies in pill form. Both pills still trail the injectables: a comparison using data from Yahoo Finance, Axios and NEJM shows the average injectable GLP-1 producing more weight loss than either pill.
Lilly’s estimated 2026 sales are $18B, against $16.5B for Novo Nordisk.
The share prices have moved apart as well. Over five days through Oct 24, Google Finance shows Lilly up 3.38% at $830.91 and Novo Nordisk down 4.39% at $52.98. Lilly’s stock has surged on trial results, while Novo’s recent slowdown highlights investor focus on innovation and novel therapy modes.
Why the pill race matters
- Ease of use: no injections, which makes the treatment preferable and supports broader adoption.
- Production scalability: pills are easier to manufacture and distribute globally.
- Healthcare access: oral forms may lower costs, improving coverage potential in insurance and public health programs.
The first company to deliver scalable, affordable and accessible oral GLP-1 therapy could dominate not just obesity, but related metabolic diseases.
Outlook
If Lilly’s orforglipron gets FDA approval, expect rapid adoption, with the oral GLP-1 becoming the dominant therapy. Oral GLP-1s are harder to absorb and deliver effectively than injectables, so both Eli Lilly and Novo Nordisk continue to innovate aggressively to close the efficacy gap with next-generation pill formulations.
Pills can also enter markets where injectables face supply chain or storage issues, such as Africa and Southeast Asia. After the oral GLP-1 is introduced, the next innovation race may include agents targeting three hormone pathways (GLP-1, GIP and glucagon), promising greater weight loss and metabolic benefits.
Some questions remain open. One is whether Lilly or Novo, with their dominance, will settle on a pill cheap enough for insurance coverage or price it like luxury wellness. Another is whether developing countries will gain access or stay behind in the “pharma fitness gap.” The short- and long-term effects of the oral pills on weight loss and obesity-related diseases also deserve a close eye.